Management Team

Arie Belldegrun, M.D., FACS

Chairman, President &
Chief Executive Officer

Dr. Belldegrun has been a leader in developing novel cancer treatments and closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. In 1996, he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman and as a board member until 2007, when it was acquired by Astellas Pharma Inc. From 2003 to 2009, he was the founding Vice-Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, Inc., until it was acquired by Johnson & Johnson. Dr. Belldegrun is the Chairman of Arno Therapeutics, Inc., Two River Group, and UroGen Pharma, Ltd. (formerly TheraCoat, Ltd.) and currently serves as a board member of Cell Design Labs. He is also a member of the Parker Institute for Cancer Immunotherapy’s Strategic Advisory Group. In addition, at the University of California, Los Angeles (UCLA), Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine. Prior to joining UCLA, he was a research fellow in surgical oncology and immunotherapy at the National Cancer Institute/NIH, working under Dr. Steven A. Rosenberg. Dr. Belldegrun earned his M.D. at the Hebrew University Hadassah Medical School in Jerusalem. He undertook his postgraduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at the Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.

Cynthia M. Butitta

Chief Operating Officer

Ms. Butitta has over 20 years of senior executive experience in the biotechnology and high-technology industries. She was most recently Senior Vice President and Chief Financial Officer of NextWave Pharmaceuticals, Inc., which was acquired by Pfizer in 2012. Prior to NextWave, Ms. Butitta served as Chief Operating Officer from 2001 to 2010 and Chief Financial Officer from 1998 to 2010 of Telik Inc., a public biotechnology company focused on the development of small molecule drugs for the treatment of cancer. While at Telik, Ms. Butitta was responsible for securing over $450 million through an IPO and subsequent follow-on offerings. From 1995 to 1997, Ms. Butitta served as Vice President of Finance and Administration and Chief Financial Officer for Connetics, Inc., a public biotechnology company. Ms. Butitta received a B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and a M.B.A. in Finance from the University of Wisconsin, Madison.

David D. Chang, M.D., Ph.D.

Executive Vice President,
Research & Development,
and Chief Medical Officer

Dr. Chang has an industry-leading track record of innovation in the field of oncology drug development. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, Dr. Chang spearheaded personalized therapy strategies that underlied the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab) a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGIC™ (talimogene laherparepvec) a first-of-its-kind oncolytic immunotherapy, in melanoma. Prior to joining Amgen, Dr. Chang held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. degree in Biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University. Dr. Chang completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.

Christine Cassiano

Senior Vice President,
Corporate Communications
and Investor Relations

With a dual background in investor and public relations, Ms. Cassiano has an extensive history developing innovative approaches that advance communications in corporate positioning, issues management, employee engagement, commercialization and investor relations. Ms. Cassiano was previously Head of Healthcare for the W2O Group, an integrated healthcare marketing and communications consulting firm. She previously co-founded ARC2 Communications & Media, a boutique agency that developed groundbreaking platforms for some of the largest companies in healthcare. Her more than 20-year career includes multiple product launches across various therapeutic areas such as Botox®/Botox® Cosmetic (onabotulinumtoxinA), Prolia® (denosumab), Abraxane® (paclitaxel) and Lumigan® (bimatoprost ophthalmic solution) as well as leading global efforts as Senior Vice President & Co-Director, Healthcare at Hill + Knowlton Strategies. Ms. Cassiano has held senior communications roles at biotechnology and pharmaceutical companies such as Amgen, Allergan and Abraxis BioScience. Some of Ms. Cassiano’s career achievements include a SABRE Silver Anvil award for the launch of Botoxâ Cosmetic (Allergan), an In2 SABRE Award for the Most Innovative Brand/Agency Collaboration (Pfizer/ARC2), and PR Week’s 40 Under 40.

Paul Jenkinson

Chief Financial Officer

Mr. Jenkinson brings nearly three decades of global financial experience in specialty pharmaceuticals and consumer product industries. From 2006 to 2015 Mr. Jenkinson worked at Allergan, Inc. From 2008 to 2015 at Allergan, Mr. Jenkinson was Vice President, Global Commercial and Corporate Finance. In this role he was responsible for the corporation’s financial planning and analysis activities and led the global commercial finance function with a focus on performance and system-wide revenue and cost management initiatives. Mr. Jenkinson worked closely with commercial operations, manufacturing operations, research and development, and general and administration functions in multiple international markets while at Allergan. From 1987 to 2006, Mr. Jenkinson held finance positions of increasing responsibility at the Black & Decker Corporation (presently Stanley Black & Decker), attaining the position of Vice President, Corporate Officer, at the Kwikset, Baldwin and Weiser Lock Companies, where he oversaw commercial finance and financial planning and analysis functions. Mr. Jenkinson qualified as an accountant while working at Deloitte earlier in his career and he continues to be an active member of Chartered Accountants Australia and New Zealand. He holds a Bachelor of Commerce degree in Accounting & Finance and Marketing from the University of Otago, New Zealand.

Helen S. Kim

Executive Vice President,
Business Development

For more than 25 years, Ms. Kim has held leadership roles in biotechnology. She served as Strategic Advisor of NGM Biopharmaceuticals, Inc. from January, 2012 to November, 2014 and as their Chief Business Officer at NGM Biopharmaceuticals, Inc. from 2009 to 2012. Prior to NGM, she was the CEO and President of Kosan Biosciences, Inc. where she restructured and repositioned the company prior to its acquisition by Bristol-Myers Squibb in 2008. Additionally, Ms. Kim’s experience includes executive positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation where she served as head of global business development and marketing for therapeutics and vaccines businesses. Ms. Kim also recently served as Chief Program Officer for the Gordon and Betty Moore Foundation. She currently serves as a board member of Sunesis Pharmaceuticals, Forsight VISION 4 and Exicure Therapeutics. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.

Tim Moore

Executive Vice President,
Technical Operations

Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Most recently, he served as Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech’s Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and the Manufacturing Leadership Council. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.

Shawn Tomasello

Chief Commercial Officer

Ms. Tomasello has over three decades of experience in Biotech and Pharma. Her leadership career has positively impacted four blockbuster products in oncology including RITUXAN®, REVLIMID®, POMALYST® and IMBRUVICA®. Previously, Ms. Tomasello was Chief Commercial Officer at Pharmacyclics until its acquisition by AbbVie. From 2005 to 2014, Ms. Tomasello held roles of increasing responsibility at Celgene Corporation, including President of the Americas, Hematology and Oncology, where she managed more than $4 billion in revenue. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of the commercial organization encompassing multiple brands spanning 11 indications. In addition, she was instrumental in strategic decision-making regarding global expansion and M&A evaluations, which led to the acquisition and integration of Pharmion Corporation, Gloucester Pharmaceuticals, Inc. and Abraxis Biosciences, Inc. Prior to joining Celgene, Ms. Tomasello was the National Director of Hematology for RITUXAN® at Genentech, where she was responsible for more than $1.7 billion in revenue and all in-line and new indications for the hematology commercial sales organization. Earlier in her career, she held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. Ms. Tomasello currently serves on the board of directors for Oxford BioTherapeutics and Diplomat. While at Celgene, she served as a board member of BIONJ and has been a member of the advisory board for Healthcare Businesswomen’s Association (HBA). Ms. Tomasello received her B.S. in marketing from the University of Cincinnati and her M.B.A. from Murray State University, KY.